Cost-Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina by Augustovski, Federico Ariel et al.
Cost-effectiveness of a Comprehensive Approach for 
Hypertension Control in Low-Income settings in Argentina: Trial-
Based Analysis of the Hypertension Control Program in 
Argentina
Federico Augustovski1,2, Martín Chaparro1, Alfredo Palacios1, Lizheng Shi3, Andrea 
Beratarrechea1, Vilma Irazola1, Adolfo Rubinstein1,2, Katherine Mills3, Jiang He3, and 
Andrés Pichon Riviere1,2
1Institute for Clinical Effectiveness and Health Policy IECS/CONICET (National Scientific and 
Technical Research Council). Address: Ravignani 2024, Buenos Aires (C1414CPV), Argentina
2School of Public Health, University of Buenos Aires. Address: Marcelo T. de Alvear 2202 PB, 
Buenos Aires (C1121ABG), Argentina
3Department of Epidemiology and Tulane University Translational Science Institute, Tulane 
University School of Public Health and Tropical Medicine, New Orleans, LA
Abstract
Background—A recent cluster randomized trial evaluating a multicomponent intervention 
showed significant reductions in blood pressure in low-income hypertensive subjects in Argentina. 
The objective of this analysis is to assess the cost-effectiveness of this intervention.
Methods—1,432 hypertensive participants from 18 primary healthcare centers. The intervention 
included community health worker-led home visits, physician education, and text-messaging. 
Resource use and quality of life using the EQ-5D-3L were prospectively collected. Study 
perspective was that of the public healthcare system, and the time horizon was 18 months. 
Intention-to-treat analysis was used to analyze cost and health outcomes (systolic blood pressure 
[BP] change and quality adjusted life years[QALYs]). A one GDP per capita per QALY was used 
as the cost-effectiveness threshold (14,062 US dollars[$]).
Results—Baseline characteristics were similar in the two arms. QALYs significantly increased 
by 0.06 (95% CI: 0.04 to 0.09) in the intervention group, and systolic BP net difference favored 
the intervention group: 5.3 mm Hg (95% CI: 0.27 to 10.34). Mean total costs per participant were 
higher in the intervention arm: $304 in the intervention group and $154 in the control group 
(adjusted difference of $140.18; 95% CI: $75.41 to $204.94). The incremental cost-effectiveness 
ratio was $3,299 per QALY (95% CI: 1,635 to 6,099) and $26 per mm Hg of systolic BP (95% CI: 
13 to 46). Subgroup analysis showed that the intervention was cost-effective in all pre-specified 
subgroups (age, gender, cardiovascular risk, and body mass index).
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Conclusions—The multicomponent intervention was cost-effective for blood-pressure control 
among low-income hypertensive patients.
Keywords
Hypertension; cost-effectiveness; primary care; low-income setting
Introduction
Hypertension is among the leading modifiable risk factors for cardiovascular disease and 
premature death worldwide,(1) and there have been significant advances in prevention and 
treatment.(2) Nevertheless, increasing prevalence and a high proportion of uncontrolled 
patients, particularly in low- and middle-income countries (LMIC), indicate that important 
gaps remain. (3, 4) Globally, almost one in three adults has hypertension, and three out of 
four live in LMIC (5). Furthermore, only around one in ten hypertensive patients in LMIC 
have their blood pressure (BP) controlled to <140/90 mm Hg. (3) It is, therefore, a key 
public health priority to develop and implement effective, affordable, and sustainable 
hypertension control programs.
The Hypertension Control Program in Argentina (HCPIA) was a cluster randomized trial(6) 
that evaluated a multicomponent intervention over 18 months among low-income patients 
with uncontrolled hypertension in Argentina. It showed significant reductions in BP in 
hypertensive subjects cared for by the national public primary health care system in 
Argentina. Though substantial reductions in BP of important clinical significance were 
demonstrated, these benefits should be weighed against costs to determine whether scarce 
healthcare system resources should be spent on this intervention or better used for other 
priorities. Previous studies evaluating the cost-effectiveness of hypertension control 
interventions in LMIC have suggested that some strategies, such as government action to 
stimulate reductions in the salt content of processed foods or combination treatment for 
people at high risk for cardiovascular disease, are cost-effective, (7, 8) but none have 
assessed a multicomponent approach. In order to assess intervention efficiency, we 
undertook a pre-specified (9) individual patient cost-effectiveness analysis of the 
multicomponent approach used in the HCPIA trial.
Materials and Methods
The results are reported according to the CHEERS reporting format for economic 
evaluations (10) and supported by the EQUATOR network. Analyses were conducted 
following state-of-the-art methods of trial-based economic evaluation.(11) The Institutional 
Review Boards of Tulane University in the US and Hospital Italiano de Buenos Aires in 
Argentina approved the study protocol with the planned economic evaluation. Informed 
consent was signed by all participants during screening. Further trial details have been 
published previously.(9)
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Target population and subgroups
The trial included adult (≥21 years old) patients and family members living in the same 
household with hypertension and uncontrolled BP (systolic ≥140 mm Hg and/or diastolic 
≥90 mm Hg on at least 2 separate visits). In addition to the main analysis, we explored cost-
effectiveness in pre-specified subgroups (gender, age, cardiovascular risk, and body mass 
index).
Setting and location
The trial was conducted in 18 public primary health care centers in poor urban areas of 
Argentina (in Buenos Aires, Misiones, Tucuman, Corrientes, and Entre Ríos provinces). 
Cluster randomization was stratified by geographic region, and primary health care centers 
were randomly assigned to the control or intervention group.
Study perspective
The study perspective was that of the healthcare system.
Comparators
The study intervention was a multi-component strategy that included a community health 
worker (CHW) home-based intervention, physician education, and a text-messaging 
intervention. CHWs educated, motivated, and facilitated communication between the 
healthcare system and patients and their families. CHWs received a 2-day interactive 
training session and onsite field testing and certification in order to facilitate behavioral 
change in home blood-pressure monitoring, medication adherence, and lifestyle 
modifications. They were also trained to function as case managers for hypertensive patients 
and their families by coordinating activities (e.g., physician consultations) and facilitating 
patient care. They visited participants’ homes monthly during the first 6 months and then 
every other month throughout the 18-month follow-up. The home-based intervention started 
with an initial 90-minute home visit where CHWs provided an automatic BP monitor, a pill 
box to organize medication, educational materials with information regarding hypertension 
management (adapted from “Your guide to Lowering Blood Pressure”)(12) and a log to 
record weekly BP values. They also taught the patient and family how to measure BP with 
the BP monitor, interpret BP values, and provided educational counseling. Subsequent home 
visits lasted 60 minutes, and CHWs provided tailored counseling to participants and their 
families on lifestyle modification, home BP monitoring, and medication adherence skills. 
Subsequent home visits also focused on goal setting, problem solving, social support, and 
maintaining motivation during challenging situations. If needed, community health workers 
also helped to schedule appointments with primary care physicians and deliver 
antihypertensive medications to patients. They also provided feedback to primary care 
physicians regarding the patients they were visiting. Primary care physicians underwent an 
online education program on hypertension management focused on treatment for stepped-
care management based on clinical guidelines (13, 14). Physicians received monthly lists of 
patients’ blood-pressure values so that medication adjustments could be made if necessary. 
Participants also received weekly personalized text-messages to promote lifestyle changes 
Augustovski et al. Page 3
Value Health. Author manuscript; available in PMC 2019 April 10.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
and reminders to reinforce medication adherence. Centers randomized to the control group 
continued with usual care without any active study intervention.
Time horizon
The trial and the economic evaluation had 18 months of follow-up, and this is the time 
horizon for this cost-effectiveness analysis.
Discount rate
Due to the short time horizon, no discounting of benefits or costs was included. A 
supplementary analysis icorporating a 5% discount rate of the 12 to 18 months period did 
not significantly altered results (see Appendix 5).
Choice of health outcomes
Protocol specified primary outcomes for the economic evaluation were Quality Adjusted 
Life Years (QALYs) and systolic BP (which was the trial co-primary outcome along with 
diastolic BP). This paper will focus on QALYs and systolic BP. Results for diastolic BP and 
hypertension control are presented in the Appendix 1.
Measurement of effectiveness
Analysis was done following the intention-to-treat principle. The EuroQol EQ-5D-3L 
instrument was administered at baseline and at 18 months, and QALYs were estimated using 
these two values per patient assuming a linear change between this two time points.(15) The 
EQ-5D-3L is the most widely used generic preference-based instrument to derive QALYs 
and has been adapted for Argentina.(16) For health state valuation, Argentinian social values 
based on the EQ-5D-3L were used.(17)
Estimating resources and costs
The study included two main cost categories from the healthcare perspective: the costs of 
implementing the intervention itself and the costs associated with the use of health services 
by individuals in both the intervention and control groups. As recommended in current 
economic evaluation guidelines, (11) protocol-driven costs (protocol visits, development of 
educational materials, etc.) were not included.
We included both the fixed and variable costs of implementing the intervention. The fixed 
costs included the development and maintenance of an on-line platform that contributed to 
the management of the intervention and generated and sent customized text messages 
promoting a healthy lifestyle to participants. The variable costs are represented by: (a) 
training activities for community health workers on the participant intervention; (b) training 
activities for physicians focused on standard treatment algorithms for stepped-care 
management based on clinical guidelines; (c) BP monitors for all hypertensive patients for 
weekly measurement; (d) the number of hours spent by community health workers on 
education, motivation, social support, and promoting healthcare utilization for participants 
and their families; (e) the number of hours spent by the community health worker 
coordinator; and, (f) the number of text messages sent to each participant. The sources of 
information used to measure and value these items were: the executed trial budget (fixed 
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intervention costs and items a, b, and c of the variable costs), administrative databases 
generated by the project at the participant level (items d, e, and f), provincial salary records 
of personnel and official labor market surveys (18) (items e and f), and telephone company 
prices (item g).
The costs of health care services used by patients were calculated using the utilization rate of 
each health care resource at the patient level and its associated unit costs in each province. 
The use of both outpatient and inpatient services (e.g. visits, medications, laboratory studies, 
hospitalization, etc.) were recorded through specific questionnaires administered at baseline, 
6 months, 12 months, and 18 months. If a follow-up questionnaire was missing data on the 
use of a specific health service, it was assumed that the utilization rate of this service was 
equal to that reported in the previous questionnaire.
Because the unit costs of health resources differ among the provinces in which the 
intervention was implemented, public sector unit costs of each province were used to 
estimate the costs of utilization of health services (19) Thus, the unit costs of health 
resources are the same for the intervention and control centers within the same province, and 
they are constant during the intervention period.
Currency, date, conversions
The costs of the development and implementation of the intervention and those associated 
with the use of health services by individuals were valued in local currency (Argentine 
pesos; AR$) and converted to US dollars as of July 2017 ($). The conversion rate used in the 
analysis was 1 US dollar = 17.169 AR$.(20)For international readers interested in valuing 
costs in International dollars, the PPP conversion factor (Argentinean pesos per international 
$) was 9.19 in 2016.(21)
Analytical methods
Differences in costs and benefits between study groups, as well as their 95% confidence 
intervals, were estimated, and incremental cost-effectiveness ratios (ICER) were reported for 
the different units of health benefit. ICERs express the amount of additional costs needed to 
achieve an additional unit of health outcome (a healthy year in the case of QALYs, a mm Hg 
in the case of BP, or an additional patient with controlled hypertension).
Intention-to-treat analyses were performed. For health outcomes, we used a multilevel 
regression model (STATA, xtmixed command) for the primary analyses, in order to account 
for the hierarchical (clustered) nature of the data. We undertook data analyses using 
generalized linear models (GLM), with appropriate family and link components, to account 
for the potentially non-normally distributed nature of data. This approach is frequently used 
in and recommended by other studies(22),(23, 24). We additionally tested GLM models with 
a beta distribution, which showed similar results to the analytical strategy described above. 
In the present paper, we present results related to the co-primary outcome of the trial 
(systolic BP change in mm Hg), as well as QALYs. The other trial co-primary outcome 
(diastolic BP change) and the proportion of hypertension control at 18 months are presented 
in the Appendix 1.
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For the primary analysis, all intervention costs were assigned to intervention groups using an 
intention-to-treat approach. Healthcare costs were retrieved at baseline and 18 months and 
included ambulatory and inpatient costs, laboratory and other diagnostic tests, and 
medications. Missing values for health and resource use outcomes were low (less than 7%) 
and not associated with the main covariables and, thus, were assumed to be missing at 
random. A complete case sensitivity analysis, including imputation of the missing values 
using the multiple imputation method, did not meaningfully change the final results. (see 
Appendix 4)
In order to define if an intervention is cost-effective, it is necessary to establish a decision 
rule, defined as a willingness-to-pay value for the outcome of interest that will be used as a 
threshold. Despite previous use and recommendations of higher thresholds, such as the 
World Health Organization’s 3 GDP per DALY recommendation,(25) we adopted a more 
stringent threshold consistent with recent studies: one GDP per capita per QALY(26–28). 
That is, if for a given intervention the ICER is above this threshold, it will be deemed too 
expensive and thus not cost-effective, whereas if the ICER lies below this threshold, the 
intervention will be judged cost-effective. The GDP per capita for Argentina used was 
14,062 US dollars or 241,430 Argentine pesos (2017 values). (29)
To incorporate uncertainty into the main outcome of the economic evaluation (the ICER), we 
estimated the ICER 95% credible interval (CI) through non-parametric bootstrapping (30–
32). Bootstrapping was conducted in cost and effectiveness simultaneously by resampling 
without replenishment from the original database. In each of the 1,000 iterations, the 
statistical means of cost and effectiveness for each group (intervention and control) were 
estimated, allowing the calculation of the 1,000 corresponding ICERs. The 95% CI of this 
variable was estimated by the percentile method.
Additionally, cost-effectiveness acceptability curves were used to graphically report the 
uncertainty around the main results and show the probability of the intervention being cost-
effective at different willingness to pay values per unit of health benefit.
Heterogeneity was explored by evaluating whether cost-effectiveness differed in pre-
specified subgroups (age, gender, history of cardiovascular disease, and body mass index).
In order to explore a potential dose-response relationship, we additionally explored whether 
the intervention differed in cost-effectiveness in patients with greater adherence to the 
intervention. This was done by stratifying patients in the intervention group by Morisky 
Medication Adherence Score,(33) number of text messages received, and number of home 
visits.
Results
A total of 1,432 hypertensive subjects were recruited from June 2013 to April 2015: 743 
from 9 intervention centers and 689 from 9 control centers. Community health workers 
completed 92.8% (8,272/8,916) of planned home-based intervention visits. Baseline 
characteristics, including quality of life and resource use, were balanced between groups 
(Table 1).
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During 18 months of follow-up, the intervention group accumulated 1.29 QALYs (95% CI: 
1.28 to 1.31), while the control group had 1.23 (95% CI: 1.21 to 1.25), for a 0.060 crude 
QALY gain. When adjusting for baseline utility and other covariables, the adjusted gain in 
QALYs was 0.042 (95% CI: 0.007 to 0.077, p= 0.017). More details of quality of life results 
are shown in Table 2. Net difference in systolic and diastolic BP were −5.3 mm Hg (95% CI: 
−10.34, −0.27; p<0.001) and −5.12 mm Hg (95% CI: −8.88, −1.36; p<0.001), respectively, 
both favoring the intervention. The net increase in the proportion of controlled hypertension 
was 20.6% (95% CI: 15.4 to 25.9%; p<0.001). Further results related to hypertension control 
and diastolic blood pressure are presented in the Appendix 1 and elsewhere.(6)
Table 3 shows intervention and non-intervention costs related to health service resource use 
at 18 months. Taking all costs into account, there was a significantly increased total mean 
cost in the intervention arm, with an increase of US $150.54 (95% CI: US $92.16 to US 
$208.92) [AR $2,584.62; 95% CI: AR $1,582.29 to AR $3,586.95] per patient, or US $8.36 
[AR $143.59] per patient per month. Patients received a median number of 12 home visits 
(IQR=11–12) and a median of 85 text messages during the intervention (IQR=81–85). Mean 
intervention 18 month costs were US $108.02 per patient (95% CI: US $59.05 to US 
$117.74) [AR $1,854.60; 95% CI: AR $1,013.83 to AR $2,021.48)]. Average health service 
use and costs not related to the intervention were similar between the two groups: US 
$196.26 (95% CI: US $0.00 to US $1,193.35) [AR $3,369.59; 95% CI: AR $0.00 to AR 
$20,488.63)] and US $153.58 (95% CI: US $0.00 to US $1,197.11) [AR $2,636.82; 95% CI: 
AR $0.00 to AR $20,553.18)] for the intervention and control groups, respectively.
ICERs were US $3,299.42 per QALY (95% CI: US $1,635.42 to US $6,099.06) [AR 
$56,647.74; 95% CI: AR $28,078.53 to AR $104,714.76] and US $26.43 per mm Hg 
systolic blood pressure reduction (95% CI: US $13.08 to US $45.91) [AR $453.78; 95% CI: 
AR $224.57 to AR $788.23]. Table 4 presents the differences in outcomes and total costs 
between groups adjusted for main individual characteristics, ICERs, and the uncertainty 
surrounding these estimates. See additional cost-effectiveness results for diastolic blood 
pressure and hypertension control in the Appendix.
Parameter estimates and global uncertainty are additionally presented as cost-effectiveness 
scatterplots and acceptability curves, which depict the probability of this multicomponent 
intervention being cost-effective at different willingness to pay values per unit of QALYs or 
mm Hg of systolic blood pressure reduction (See Figure 1). There is a 100% certainty that 
the intervention would be cost-effective at a willingness to pay per QALY of 1 GDP per 
capita (see Appendix 3 for acceptability curves for diastolic blood pressure and hypertension 
control).
In pre-specified subgroup analyses the intervention was cost-effective in all subgroups. 
Though results were less precise when analyzing subgroups, they showed the intervention 
was somewhat more cost-effective in younger ages (ICER: US $2,156.19 [AR $37,019.63] 
per QALY), in women (ICER: US $3,292.60 [AR $56,530.65] per QALY), in subjects with 
higher cardiovascular risk (ICER: US $2,726.09 [AR $46,804.24] per QALY), and in those 
with high body mass index (ICER: US $1,796.17 [AR $30,838.44]). The intervention was 
also somewhat more cost-effective in those with a lower Morisky adherence score (see Table 
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5). The results of cost-effectiveness by number of text messages and home visits received 
suggested the intervention was more cost-effective in those groups with a less intense 
intervention dose (see Appendix 2 for results).
Discussion
The present study is, to our knowledge, the first randomized cluster trial-based economic 
evaluation to assess a multicomponent intervention led by community health workers, 
including complementary physician education and a mobile health intervention, in a low-
resource setting in LMICs. This trial among low-income hypertensive patients receiving care 
from public primary health care centers showed that the intervention, over an 18 month time 
horizon, was more effective than usual care in reducing blood pressure and increasing 
healthy years of life. Adherence to the community health worker-led intervention, including 
home visits, was very high in our study. In Argentina, community health workers are 
integrated into the primary care team, so this facilitated their recruitment and training for 
this trial. The public primary care network also has clinics located in low-resource settings 
and provides medications for chronic diseases free of charge, so the infrastructure is in place 
to provide access to care for low-income hypertensive participants. The intervention was 
more costly than usual care (US $8.36 [AR $143.59] per patient per month) and was shown 
to be a cost-effective strategy when a one GDP per QALY threshold was used. The main 
results were robust, as our analysis showed that when using a one GDP per QALY threshold, 
this intervention had a 100% probability of being cost-effective.
Approximately 80% of all cardiovascular mortality occurs in LMICs, where the greatest 
burden of hypertension is observed.(3, 34) Despite the availability of affordable 
antihypertensive medications and lifestyle interventions, the proportion of hypertension 
control remains low.(3, 35–37) The results of this study show that a multicomponent 
intervention led by community health workers could be a cost-effective strategy to improve 
hypertension control in LMICs. If scaled-up, it could result in a significant reduction in 
uncontrolled hypertension and related cardiovascular disease by overcoming key barriers 
that are currently a major obstacle for hypertension control both in LMICs and in 
underserved populations in high-income countries.(38)
This is the first economic evaluation of a multicomponent community health worker-led 
intervention similar to ours in a LMIC setting. Our results show that the HCPIA intervention 
had similar or better cost-effectiveness than several strategies for hypertension control tested 
in low resource settings, such as multidrug or polypill therapies in high cardiovascular risk 
populations, community health workers to improve medication adherence, and clinical 
decision support systems. Table A3 shows our results compared to results of other relevant 
studies that used QALYs, disability-adjusted life years (DALYs), or blood pressure change 
as health outcomes.
Our study has some limitations. First, the time horizon was short relative to the relevant 
decision-making timeframe. This is a common limitation of trial-based economic 
evaluations. Second, our study was done from the healthcare perspective, so we did not 
include other societal costs, such as productivity costs, transportation costs, and other direct 
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non-medical costs, which is increasingly recommended. (39) Third, though the study was 
undertaken in a real-life setting, and protocol related costs were not included it was an 
experimental trial. This is a well-known limitation of trial-based economic evaluations. (40)
In conclusion, our study found that among low-income patients with uncontrolled 
hypertension in Argentina, a multicomponent intervention led by community health workers 
was cost-effective. The intervention significantly improved blood pressure control and 
quality of life over an 18-month intervention at reasonable incremental costs.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
1. What is already known about the topic?
Multicomponent interventions, including community health worker and 
mobile health strategies, to control hypertension have been shown to be 
effective in some settings and to be cost-effective in high-income countries. 
No previous economic evaluation based on a rigorous randomized trial in 
low-income settings has been reported.
2. What does the paper add to existing knowledge?
This economic evaluation based on a cluster randomised trial in a low-income 
setting gives a detailed account of the effects and costs of implementation of a 
multicomponent intervention. The intervention significantly increased years 
of healthy life (QALYs) and improved blood pressure at small additional costs 
to the healthcare system, confirming its cost-effectiveness in this setting. The 
robust results, which demonstrated consistent evidence of cost-effectiveness 
regardless of methodologic assumptions and across subgroups of age, gender, 
cardiovascular risk, and body mass index, leave little uncertainty about the 
cost-effectivness of the intervention in this setting.
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Fig. 1. 
Scatterplots and cost-effectiveness acceptability curves depicting the uncertainty around 
main study results.
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